Since many of the severe cytomeqalovlrus infections in humans occur in individuals im,[fiunosuppressed by the human immunodeficiency virus, we developed an analogous murine model for studying this disease. BALB/c mice infected with the Friend retrovirus complex (FV)were immunosuppressed (i.e., exhibited reduced spleen-cell mitogenic responses and natural killer cell activity) by 21 days after FV inoculation. Challenge with murine cytomegalovirus (MCMV) at that time led to mortality at doses generally non-lethal to normal mice. Superinfection of FV-infected mice with MCMV reduced spleen cell FV infectious centres and splenomegaly, and extended the lives of mice surviving the MCMV infection. Once-daily ganciclovir treatments of 12.5, 25, and 50mg kg-1 given to duallyinfected mice for 5 days starting 24h after MCMV inoculation resulted in 90-100% survival at 14 days (relative to MCMV inoculation) compared to 15% survival in the placebo group. By 70 days, survival in the drug-treated and placebo groups were' Q-5%, these deaths being attributed to FV disease. Ganciclovir treatments reduced MCMV titres in spleen, liver, and kidney during treatment (day 4 of the infection), but lung and salivary gland titres rose between days 7 and 13 in surviving animals. Improved concanavalin A-induced mitogenic responses were noted on day 4 in mice treated with 25 and 50 mg kg-1. These results indicate that the FV/MCMV dual infection in mice can be used as a model for evaluating antiviral agents. Because of the complex nature of the interaction between FV and MCMV, the model may be more 
Introduction
Human cytomegalovirus (HCMV)causes generally benign disease in immunocompetent adults, but afflicts newborns (yow, 1989) and adults immunosuppressed by chemotherapy (Dowling et aI., 1976; Salmela et al., 1990) or by human immunodeficiency virus (HIV) infection (Nelson et st., 1990; Pulakhandam and Dincsoy, 1990) . In HIV-infected individuals Whohave progressed to the point of having AIDS (acquired immune deficiency syndrome), HCMV retinitis, pneumonitis, and gastritis may occur (Tyms et al., 1989) . Recently the nucleoside analogue ganciclovir (GCV) was approved for the treatment of HCMV retinitis (Laskin et al., 1987a (Laskin et al., , 1987b in AIDS patients, and is undergoing clinical trials to treat other conditions caused by HCMV (Schooley, 1990) .
Murine cytomegalovirus (MCMV) infection of mice represents a viable model of HCMV infection (Hudson, 1979) and for evaluating drug treatments (Kelsey et el., 1976; Freitas et al., 1985) . In addition, mice infected with various retroviruses, including the Friend virus complex (FV) (Morrey et al., 1990) , have been recently employed for studying substances with potential anti-HIV activity. It is known that genetically-associated immunosuppression and that induced by treatment with certain chemical substances leads to enhanced MCMV infection (Grundy JChalmer] and Melief, 1982) . Since FV-infected mice become immunosuppressed (Dent, 1972; Morrison et aI., 1986; Morrey et al., 1990) , we hypothesized that FVI MCMV dual infection would be more severe than MCMV infection alone. In this report the FV/MCMV model is described and data are presented of GCV's activity against the MCMV component of the infection.
Results

Establishment of dual infection model
After titrating MCMV and FVseparately to determine lethal doses of each, the appropriate doses of each virus, first FV and then MCMV, were given intraperitoneally to mice 21 
Ganciclovir therapy of FVIMCMV infection
GCV treatments of :;;;;50mg kg-1 were not toxic in these experiments since weights of drug-treated uninfected toxicity control mice were essentially the same as placebo (saline-treated) controls, and no mice died from drug treatment (data not shown). Mice infected with FV(640 IC) and then with MCMV (3 x 10 5 p.t.u.) 21 days later were treated with GCV for 5 days starting 24 h after MCMV inoculation (Fig. 1) . In this experiment the FV/MCMVinfected placebo group had 85% mortality 7 days after MCMV challenge compared to Q-.10% mortality in GCV groups treated with 12.5,25, and 50mg kg-1 (P < 0.01).
Untreated mice infected with only MCMV survived the infection. Untreated animals infected with only FV had 30 and 100% mortality on days 7 and 35 (relative to MCMV infection), respectively. In contrast, GCV-treated, FVI MCMV-infected mice died much more slowly from apparent FV infection, with mean survival times being statistically significant (P < 0.01) compared to the FVinfected control. Mice infected only with FV and treated with GCV for 5 days starting 22 days after FV challenge died similarly to matched placebo controls (data not shown), indicating a lack of anti-retroviral activity by GCV.
GCVtreatments significantly reduced MCMV virus titres in tissues 4 days after MCMV inoculation in FV/MCMVinfected and in MCMV-infected mice (fable 1). Spleen virus titres were similar between the MCMV-infected and the FV/MCMV-infected placebo groups, whereas liver, lung, and kidney virus titres were higher in the dually-infected placebo group, indicating a more severe infection. GCV therapy significantly reduced MCMV titres in spleen and liver when compared to the respective placebotreated infected control groups. MCMV titres were also determined at later times during the infection. This required maintaining many extra mice, particularly since most of the FV/MCMV placebo group died from the infection by day 8. In these studies, detectable virus persisted in the liver, kidney, and spleen only through day 7 (data not shown). However, lung and salivary gland MCMV titres in placebo controls and in GCV-treated groups rose over time (Fig. 2 ). MCMV titres in FV/MCMVinfected mice on day 13 were higher than in MCMV-infected animals in placebo-treated and GCV-treated groups. It should be pointed out that the data from the FV/MCMVinfected placebo control group for days 10 and 13 are representative from a small subset of mice surviving the MCMV infection, since most of the mice would have died before achieving these lung and salivary gland viral titres.
In order to understand the effect of dual infection and the influence of GCV therapy on FV disease, FV infection parameters were determined (fable 2). On day 4 after MCMV inoculation, the FV/MCMV-infected placebo control and GCV-treated groups had dramatically reduced splenomegaly relative to the FV-infected placebo group. Spleen weights of FV-infected mice sacrificed for this purpose on day 21 (day 0 of MCMV infection in other mice) were> 1g each, indicating that superinfection with MCMV actually reduced splenomegaly by 4 days after MCMV inoculation. Mice infected only with FV would have had increased in splenomegaly from day 21 to day 25 (day 4 of the MCMV infection in other mice). FV titres in FVlMCMVinfected mice were significantly less than the FV-infected placebo group except for animals treated with the highest dose of GCV. On day 4, dually-infected mice treated with 50 mg GCV kg-1 had much higher FVtitres (P < 0.01) than the respective placebo control. By day 10 of the infection, FV tit res and splenomegaly in the dually-infected groups were similar to those in the FV-infected groups. Finally, GCV treatments did not have a significant effect on splenomegaly and FV titres in FV-infected mice.
Various immune parameters were determined during the dual infection (fable 3). FV-infected and MCMV-infected mice had reduced Con A and NK cell responses relative to uninfected animals (P < 0.01). Dual infection may have further depressed the Con A response (day 7 only) but not the other immunologic activity. Treatment with GCV at 25 and 50mg kg-1 significantly improved the Con A response relative to the placebo control. GCV treatment did not cause a significant improvement in NK cell activity in coinfected mice. LPS responses were not appreciably altered during any of the infections. 15.4 ± 12.1 16.9 ± 19.5 11.7 ± 9.5 18.0 ± 11.3 a Relative to MCMV challenge. FV was inoculated 21 days prior to MCMV. b GCV and placebo were administered once daily for 5 days starting 1 day after MCMV inoculation. c Spleen weights in uninfected mice or in mice infected only with MCMV ranged from 0.08 to 0.12 g. 
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Discussion
Infection of BALB/c mice with FVled to an enhancement of subsequent MCMV infection, based upon increased mortality and higher virus titres in certain organs of duallyinfected, compared to' MCMV-infected animals. This effect was dependent upon the dose of each virus used, since either virus (at high enough dose) was capable of killing the animals by itself. Each infection was shown to suppress immunologic parameters (Con A and NK cell responses), and the dual infection led to further decreases in Con A responses (T-cell blastogenesis). The increased liver virus titre in FV/MCMV-infected mice relative to MCMV-infected animals (Table 1 ) may be the cause of enhanced lethality, based upon previous work suggesting this as the key organ involved in MCMV-induced mortality (Overall et aI., 1976) .
The results indicate that MCMV infection temporarily delays proqression of FV disease in dually-infected mice by inhibiting splenomegaly and FV titres. Consequently, survivors of the MCMV phase of the FV/MCMV infection live longer than mice infected only with FV. Since GCV inhibits MCMV replication, one would hypothesize that the more active drug doses would reverse the inhibitory effects of MCMV on FV disease progression. Likewise, less active drug doses (allowing MCMV replication) would be more favourable to allow prolonged survival during FV infection. This indeed appears to be the case, since the FV titres in FV/MCMV-infected mice treated with 50 mg GCV kg-1 were nearly as high as in the FV-infected placebo group (Table 1 ). In addition, the survival patterns on Fig. 1 suggest that FV/MCMV-infected mice treated with 12.5mg GCV kg-1 lived longer than those receiving the higher dose of drug. How MCMV interferes with the course Of FV disease needs to be further investigated. Specifically, we plan to address how and why FV-infected spleens decrease in weight after superinfection with MCMV. The interaction of these two viruses appears to differ from that of HCMV and HIV, since enhanced HIV replication occurs in HIVlHCMV infected cells (Ho et et., 1990) .
The results from these experiments indicate that all 3 doses of GCV were beneficial to survival from the MCMV infection but not the FV infection. Each drug dose also inhibited MCMV tit res in tissues on day 4 to nearly the same degree in dually-infected animals. At 7, 10, and 13 days there appeared to be a more dose-responsive inhibition of lung and salivary gland MCMV titres, with 50 mg kg-1 being the most active. Also, the Con A response was least improved in mice receiving the 12.5mg kg-1 dose. In order to more effectively determine antiviral potency, these studies will have to be repeated using GCVbelow 12.5mg kg-1 to determine weakly active or inactive doses.
Variability in the time of death by a particular FVinfecting dose occurs from experiment to experiment. Ideally, one would want deaths from FV infection to start after 14 days of MCMV superinfection, but as was evident in Fig. 1 this may not be the case. Earlydeaths due to FVinfection (such as those demonstrated in the FV-infected control group of Fig. 1 ) will obscure the MCMV mortality results between days 0 and 8 of the MCMV infection. For example, in Fig. 1 one mouse in the 50mg kg-1 GCV group died a day after MCMV inoculation (22 days after FV challenge), presumably from FVinfection. The effect of GCV to improve the Con A response in FV/MCMV-infected mice is similar to the compound's effect in a recent report of MCMV infection in mice immunosuppressed with cyclophosphamide (Smee et aI., 1991) . This may relate to the anti-MCMV activity of the compound, since MCMV infection reduces the Con A response below that already caused by FV infection. The increase in Con A response caused by GCV treatment brought this immunological activity back to the level observed in FV-infected mice but which was still below that of uninfected (normal) mice, indicating a lack of anti-retroviral activity.
De Castro and colleagues (1991) developed a dual infection mouse model similar to ours using the LP-BM5 retrovirus (murine AIDS or MAIDS virus) and MCMV. After 100 days of MAIDS infection the immunosuppressed animals were more susceptible to MCMV infection at particular infecting doses. GCVwas effective in preventing MCMV-induced mortality in that model at doses and treatment regimens similar to those reported here. The experiments of De Castro et al. (1991) did not address the relationship between retroviral and MCMV infections nor the effect of antiviral treatment on the retroviral component of the disease, and animals were not held for death due to MAIDS disease. The advantage of the FV model is that it takes only 21 days of FV infection to achieve sufficient immunosuppression as opposed to 100 days with the MAIDS virus.
The FV/MCMV infection model is somewhat analogous to HCMV infections in AIDS patients (Tyrns et st., 1989) , since in both cases imrnunpsuppresslon leads to enhanced cytomegalovirus disease. However, this model does not lend itself to routine screening of potentially new anti-MCMV agents because of the complex interaction between MCMV and FV in vivo which requires some sorting out. The model may be applicable to conducting more advanced studies using previously characterized anti-MCMV agents (Snoeck et al., 1988) , anti-retroviral compounds (Morrey et al., 1990) , broad-spectrum compounds (DeClercq et al., 1986) , or biological response modifiers (Brideau and Wolcott, 1985) .
Materials and Experimental procedures
Viruses ana cells
The Smith strain of MCMV was obtained from the American Type Culture Collection (ATCC),Rockville, MD. The virus was prepared for animal studies by passage in 3-week-old BALB/c mice, with mice killed 12 days after intraperitoneal (Lp.) injection of a sub-lethal dose. Ten percent homogenates of salivary glands were prepared using cell culture medium as described (Freitas et et., 1985) . The homogenates were clarified by centrifugation at 600 x g for 10 min at 4°C and aliquots stored at -80°C in cryotubes. The Lilly-Steeves B-tropic strain of FV, originally obtained from Frank Lilly, Albert Einstein School of Medicine, Bronx, NY, was also used. The virus was provided to us courtesy of Bruce Chesebro, NIAID, Rocky Mountain Laboratories, Hamilton, MT. The virus was passaged by l.p, injection in 4-6-week-old BALB/c mice. At 14 days the spleens were removed and 10% homogenates made (Morrey et al., 1990) , which were then Clarifiedby centrifugation and stored frozen similar to MCMV. The MCMV pool was titrated at different dilutions in BALB/c mice to determine the lowest dose of virus causing 90-100% mortality. This dose was used for subsequent chemotherapy experiments.
The FV was similarly titrated and a minimum lethal dose selected which generally caused mortality after 35 days of infection, but was also sufficiently potent to induce uniform immunosuppression of a group of mice. C1271 (mouse mammary tumour) cells and YAC-1 (mouse lymphoma) cells, were purchased from ATCC. Mus dunni cells (Chattopadhyay et al., 1981) were obtained from SisirChattopadhyay, National Institutes of Health, Bethesda, MD.
Animals
Six-week-old female BALB/c mice were provided by Simonsen Laboratories (Gilroy, CAl. Only animals certified free of common pathogens were used. Upon arrival, each group was quarantined for at least 24h, and fed Wayne Lab Blox (Murray Feed Co., Murray, UT) and tap water ad libitum. Initially there were 20 mice per group held for death in the FV/MCMV placebo and the FV-infected groups, and groups of 10 mice used for GCV treatments. Groups of 30-50 mice treated with drug or placebo were held for immunologic and virus titre determinations. This included extra mice that would die from infection before these assays could be conducted. In all studies, FV-and MCMV-infected mice were age-matched with FV/MCMV-infected animals during infections and treatments.
Drug treatments and toxicity determinations
Ganciclovir [GCV; 9-(1,3-dihydroxy-2-propoxymethyl)guanine] was kindly provided by Elmer Reist, SRI International, Palo Alto, CA. It was dissolved in saline for animal treatments and administered i.p. once daily for 5 days starting 24h after MCMV inoculation. Saline served as the placebo control in infection studies and in preliminary toxicity determinations. GCV was evaluated for toxic effects in uninfected mice at the same doses and treatment regimens used for antiviral studies. These toxicity studies were run in parallel with drug efficacy experiments. The weight of these mice before the first treatment and 24 h after the last treatment were recorded. Normal (untreated) mice were weighed at the same times as drug-and placebo-treated groups. Five mice were used in each toxicity and normal control group. Animals were observed daily for death, and mean survival times were determined.
Virus titre determinations
One-half log10serial dilutions of 10% mouse tissue homogenates in cell culture medium were applied to C1271 cells (Smee et al., 1989) in 96-well plates to titrate for MCMV. Five mice per group had tissue samples taken for titrations, and each sample was titrated separately. Plates were read by microscopic examination at 4 and 7 days to detect MCMV-induced cytopathology. All wells positive for virus were used to determine 50% endpoints calculated by the method of Reed and Muench (1938) . MCMV titres were expressed as Log 10 50% cell culture infectious doses per gram oftissue (Log 10 CCID sog-1). This method is about one tenth as sensitive as the plaque reduction assay for virus titre quantitation, but allows a larger number of samples per unit time to be assayed. Each sample can then be assayed separately to calculate geometric means virus titres with standard deviations.
Other investigators who use the plaque assay method combine virus-containing tissue homogenates from 3 or more animals before titrating the pooled samples (Overall et al., 1976) which gives an arithmetic mean titre, or use fewer numbers of mice (De Castro et a/., 1991) which increases variability, so the sensitivity they gain by using the plaque assay is lost elsewhere.
A focal immunofluorescence assay (Sitbon et a/., 1985; Evans and Morrey, 1987) 
Immunological assays
Freshly removed spleens were homogenized with a Stomacher (Tekmar Co., Cincinnati, OH) to create single cell suspensions. The red cells in the preparations were lysed for 15s in water, and the remaining lymphoid cells were quickly brought back to a physiological condition by adding 10 x phosphate buffered saline (PBS). Subsequently, the remaining cells were washed 2 x in PBS then counted with a Coulter counter (Coulter Electronics, Hialeah, FL). The numbers of these cells used for immunological assays are given below. RPMI1640 containing 10% FBS, 10mM HEPES buffer and 2 mM glutamine was used as assay medum. Spleen cells from 5 mice per group were assayed individually as described below. The number of spleen lymphocytes used was standardized in each assay and did not depend upon the initial weight of the spleens upon removal from the animal. This was done since FV infection caused marked splenomegaly whereas MCMV infection decreased spleen weights; and different amounts of Iymhocytes were recovered in each circumstance. Even though FV infection increases the percentage of nucleated red cells, which would normally be counted by a Coulter counter, the lysis technique eliminates the majority of these cells. We have found this method will provide lymphocyte populations with a similar degree of Con A-stimulatory activity as those obtained using a standard nylon wool-passed cell separating procedure to recover T-lymphocytes (Julius et a/., 1973) , indicating that contaminating non-lymphocyte cells are efficiently removed. T-cell blastogenesis assays were conducted using spleen cells (1 x 10 5 cells per well, 3 wells per sample) in 96-well plates incubated with 25 fL9 of concanavalin A (Con A, aT-ceil mitogen) per ml for 48 h at 3rC. At 24 h, [3H]thymidine (ICN Radiochemicals, Irvine, CAl at 0.5 u.Ci per well was added. At the end of the incubation period the cells were collected on glass fibre filters, washed and lysed with water to remove unincorporated material, and the filters were counted for radioactivity using a scintillation counter. Counts were expressed as mean thymidine incorporation ± standard deviation. These and similar methods were described previously (Selgrade et a/., 1982; Morrey et el., 1990 ).
B-cell blastogenesis assays were performed identical to T-cell assays except that 20 fL9 of lipopolysaccharide (E. coli type 055:B5 [Sigma, Chemical Co.], a B-cell mitogen) was used instead of Con A (Selgrade et a/., 1982; Brideau and Wolcott, 1985) .
Natural killer (NK) cell activity was determined using spleen cells (1 x 10 6 cells per well for effector-to-target cell ratio of 100:1, 3 wells per sample) in 96-well plates combined with YAC-1 target cells. The YAC-1 cells were previously labelled with [
5 1Cr] (1 00 fLCi rnr ' for 1 h, then PBS washed, incubated 30 min, then washed again prior to use) before combining with the effector cells. The combined cells were centrifuged at 100 x g for 3 min, incubated at 3rC for 4 h, centrifuged again for 5 min at 500 x g, then 100 fLl of cell-free supernate from each well was directly counted using a gamma counter. Untreated controls consisted of target cells minus effector cells (spontaneous counts released) and cells treated with 1% Triton X-100 (maximum counts released). The per cent cytotoxicity for each sample was the difference between experimental counts and spontaneous release counts divided by the difference between maximum release counts and spontaneous release counts times 100. These methods have been described previously (Morrey et el., 1990; Smee et el., 1990) .
Statistical analyses
Survivor increases were assessed using the Fisher exact test. Mean survival time increases and differences in tissue virus titres were evaluated using the Mann-Whitney U-test. Differences in spleen weights and immunological parameters were compared using the Student's t-test. All analyses were two-tailed and compared GCV-treated groups to respective placebo controls except where indicated in the tables.
